Modulation of nuclear factor-κB-mediated pro-inflammatory response is associated with exogenous administration of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis

Zuo,Dongmei; Tang,Qing; Fan,Heng; Shou,Zhexing; Liu,Xingxing; Cao,Dan; Zou,Zhou

doi:10.3892/mmr.2014.3038

Modulation of nuclear factor-κB-mediated pro-inflammatory response is associated with exogenous administration of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis

Authors:
- Dongmei Zuo
- Qing Tang
- Heng Fan
- Zhexing Shou
- Xingxing Liu
- Dan Cao
- Zhou Zou
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: December 3, 2014 https://doi.org/10.3892/mmr.2014.3038
Pages: 2741-2748

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) inhibit the immune response in vitro and prevent the induction of disease in certain experimental models. As a result, MSC‑mediated therapy is a rapidly growing field of research. However, the efficacy of MSCs in the treatment of inflammatory bowel disease (IBD) has remained to be determined. In the present study, rats with 2,4,6‑trinitrobenzene sulfonic acid (TNBS)‑induced colitis were injected with prepared MSCs (1x106) into the tail vein. Two weeks following intravenous MSC administration, the concentration of tumor necrosis factor‑α (TNF‑α) in the serum was measured by an ELISA. The protein expression of nuclear factor‑κB (NF‑κBp65) in the colonic mucosa was assessed by western blot analysis. mRNA expression of TNF‑α and NF‑κBp65 was determined by reverse‑transcription quantitative polymerase chain reaction. MSCs were shown to exert an immunomodulatory effect on TNBS‑induced colitis and may be of use in the treatment of IBD. In addition, modulation of the NF‑κB‑mediated pro‑inflammatory response may contribute to the underlying mechanism by which MSCs ameliorate the clinical and histological changes associated with IBD.

View Figures

View References

1	Schirbel A and Fiocchi C: Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis. 11:266–276. 2010. View Article : Google Scholar : PubMed/NCBI
2	Baumgart DC and Carding SR: Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–1640. 2007. View Article : Google Scholar : PubMed/NCBI
3	Hisamatsu T, Kanai T, Mikami Y, et al: Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol Ther. 137:283–297. 2013. View Article : Google Scholar
4	Műzes G, Molnár B, Tulassay Z and Sipos F: Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol. 18:5848–5861. 2012. View Article : Google Scholar :
5	Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007. View Article : Google Scholar : PubMed/NCBI
6	de Zoeten E and Mamula P: What are the guidelines for using biologics in pediatric patients? Inflamm Bowel Dis. 14(Suppl 2): S259–S261. 2008. View Article : Google Scholar : PubMed/NCBI
7	Taba Taba Vakili S, Taher M and Ebrahimi Daryani N: Update on the management of ulcerative colitis. Acta Med Iran. 50:363–372. 2012.PubMed/NCBI
8	Parekkadan B and Milwid JM: Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 12:87–117. 2010. View Article : Google Scholar : PubMed/NCBI
9	Meyerrose T, Olson S, Pontow S, et al: Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev. 62:1167–1174. 2010. View Article : Google Scholar : PubMed/NCBI
10	Le Blanc K, Tammik C, Rosendahl K, Zetterberg E and Ringdén O: HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 31:890–896. 2003. View Article : Google Scholar : PubMed/NCBI
11	Le Blanc K, Tammik L, Sundberg B, Haynesworth SE and Ringdén O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 57:11–20. 2003. View Article : Google Scholar : PubMed/NCBI
12	Dalal J, Gandy K and Domen J: Role of mesenchymal stem cell therapy in Crohn’s disease. Pediatr Res. 71:445–451. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ringdén O, Uzunel M, Rasmusson I, et al: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 81:1390–1397. 2006. View Article : Google Scholar : PubMed/NCBI
14	Sun S, Guo Z, Xiao X, et al: Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells. 21:527–535. 2003. View Article : Google Scholar : PubMed/NCBI
15	Morris GP, Beck PL, Herridge MS, et al: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:795–803. 1989.PubMed/NCBI
16	Davaatseren M, Hwang JT, Park JH, et al: Poly-γ-glutamic acid attenuates angiogenesis and inflammation in experimental colitis. Mediators Inflamm. 2013:9823832013. View Article : Google Scholar
17	González R, Rodríguez S, Romay C, et al: Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Parmacol Res. 39:55–59. 1999.
18	Guo Y, Su L, Wu J, et al: Assessment of the green fluorescence protein labeling methods for tracking implanted mesenchymal stem cells. Cytotechnology. 64:391–401. 2012. View Article : Google Scholar : PubMed/NCBI
19	Yi T and Song SU: Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 35:213–221. 2012. View Article : Google Scholar : PubMed/NCBI
20	Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8:726–736. 2008. View Article : Google Scholar
21	Tolar J, Le Blanc K, Keating A and Blazar BR: Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 28:1446–1455. 2010. View Article : Google Scholar : PubMed/NCBI
22	Krampera M, Cosmi L, Angeli R, et al: Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 24:386–398. 2006. View Article : Google Scholar
23	Tanaka F, Tominaga K, Ochi M, et al: Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 83:771–779. 2008. View Article : Google Scholar : PubMed/NCBI
24	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
25	Idriss HT and Naismith JH: TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 50:184–195. 2000. View Article : Google Scholar : PubMed/NCBI
26	Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
27	Smith CA, Farrah T and Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:959–962. 1994. View Article : Google Scholar : PubMed/NCBI
28	Ogata H and Hibi T: Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des. 9:1107–1113. 2003. View Article : Google Scholar : PubMed/NCBI
29	Zheng L, Fisher G, Miller RE, et al: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 377:348–351. 1995. View Article : Google Scholar : PubMed/NCBI
30	Noti M, Corazza N, Mueller C, Berger B and Brunner T: TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med. 207:1057–1066. 2010. View Article : Google Scholar : PubMed/NCBI
31	Olson TS, Reuter BK, Scott KG, et al: The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 203:541–552. 2006. View Article : Google Scholar : PubMed/NCBI
32	Reimund JM, Wittersheim C, Dumont S, et al: Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn’s disease. J Clin Immunol. 16:144–150. 1996. View Article : Google Scholar : PubMed/NCBI
33	Armuzzi A, Lionetti P, Blandizzi C, Caporali R, et al: Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol. 27(1 Suppl): 11–32. 2014.PubMed/NCBI
34	Chen FE and Ghosh G: Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene. 18:6845–6852. 1999. View Article : Google Scholar : PubMed/NCBI
35	Barnes PJ and Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1066–1071. 1997. View Article : Google Scholar : PubMed/NCBI
36	DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E and Karin M: A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 388:548–554. 1997. View Article : Google Scholar : PubMed/NCBI
37	Schmitz ML, Bacher S and Kracht M: I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci. 26:186–190. 2001. View Article : Google Scholar : PubMed/NCBI
38	Pizarro TT and Cominelli F: Cytokine therapy for Crohn’s disease: advances in translational research. Annu Rev Med. 58:433–444. 2007. View Article : Google Scholar
39	Elson CO, Cong Y and Weaver CT: Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterol. 132:2359–2370. 2007. View Article : Google Scholar
40	Atreya R, Mudter J, Finotto S, et al: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 6:583–588. 2000. View Article : Google Scholar : PubMed/NCBI
41	Suenaert P, Bulteel V, Lemmens L, et al: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol. 97:2000–2004. 2002. View Article : Google Scholar : PubMed/NCBI